Cyclin E1 amplification and overexpression are associated with poor prognosis in BC[132], while CCNE1 amplifications[71,133], cyclin E1 upregulation[73], and an elevated CCNE1/RB1 ratio[74] correlate with CDK4/6i resistance. Here, CDK4 is linked to breast cancer.